64.35
+13.97%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Eton Pharmaceuticals
From its filings with the US Securities and Exchange Commission
Eton Pharmaceuticals is based in Deer Park, Illinois and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker ETON. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $80.0m and a net loss of $4.6m. At that date it held total assets of $92.1m and shareholders' equity of $26.2m. By business, Product Sales and Royalties [Member] brought in 95.9% of revenue, followed by License [Member] at 4.1%.
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. We currently have eight commercial rare disease products: INCRELEX®, ALKINDI SPRINKLE®, KHINDIVITM, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. We have five additional product candidates in late-stage development: ET-600, Amglidia®, ET-700, ET-800 and ZENEO® hydrocortisone autoinjector.
INCRELEX® – This biologic product was approved by the FDA in August 2005 as a treatment for children who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). The product is approved in 40 territories, including the United States and the European Union. We acquired and launched the product in December 2024.
ALKINDI SPRINKLE® – This product was approved by the FDA in September 2020 as a replacement therapy for Adrenocortical Insufficiency (“AI”) in children under 17 years of age. The product is the first and only FDA-approved granule hydrocortisone formulation designed to help provide accurate dosing for newborns and children with AI. We acquired U.S. marketing rights to the product in March 2020 and launched ALKINDI SPRINKLE® in December 2020 with a sales force targeting pediatric endocrinologists. We believe there are approximately 10,000 children currently suffering from AI in the United States. ALKINDI SPRINKLE® is protected by three issued patents that extend to 2032, 2033, and 2034.
Quoted from its 10-K, filed 19 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 9 Nov 2018
- Employees
- 44
- Website
- etonpharma.com ↗
- Head office
- 21925 W. FIELD PARKWAY, DEER PARK, IL, 60010-7278
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. Norbert RiedelIndependent Chairman of the Board$188,586
- Mr. Sean BrynjelsenPresident, Chief Executive Officer, Director, since 2017$2.4m
- Mr. James GruberChief Financial Officer, Treasurer, Secretary$1.1m
- Ms. Ipek Erdogan-TrinkausChief Commercial Officer$775,488
- Mr. David KrempaChief Business Officer$1.3m
- Ms. Jennifer AdamsIndependent Director$150,730
- Mr. Charles CasamentoIndependent Director$158,842
- Mr. Paul MaierIndependent Director$161,546
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 23
- Environment
- 23
- Social
- 37
- Governance
- 8
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Strong product portfolio comprising a diverse range of pharmaceuticals.
- Well-established presence in the pharmaceutical industry.
- Robust distribution network, ensuring wide market reach.
Weaknesses
- Relatively small market share compared to larger pharmaceutical companies.
- Limited financial resources for research and development.
- Vulnerability to changes in regulatory environment and pricing pressures.
Opportunities
- Potential for expansion into emerging markets with increasing healthcare needs.
- Growing demand for specialized pharmaceuticals targeting specific medical conditions.
- Collaborations and partnerships with other pharmaceutical companies for joint product development.
Threats
- Intense competition from larger pharmaceutical companies with greater resources.
- Regulatory challenges and stringent approval processes for new drug releases.
- Fluctuations in healthcare policies and reimbursement systems impacting pricing and market access.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.